Bio
Dr. Hu received his PhD training from University of Colorado Health Sciences Centre in 2001~2007 and then postdoctoral training at Washington University in St. Louis and Howard Hughes Medical Institute in 2008~2013. Since November 2014, Dr. Hu has joined National Cancer Centre Singapore and Duke-NUS Cancer and Stem Cell Program, and served as the Principal Investigator/Assistant Professor at the Laboratory of Cancer Signaling. He has significantly contributed to our understanding of molecular mechanisms that govern the RAS/RAF/MEK/ERK signaling in normal and cancer cells (Hu et al., PNAS, 2011, Cell, 2013; Yuan et al., Oncogene, 2018, Sci. Signal., 2018) and underlie RAF inhibitor resistance in targeted cancer therapy (Yap et al., Sci Adv. 2021). His research interest focuses on (1) the regulatory mechanism of RAS/RAF/MEK/ERK signaling under normal/pathological conditions, (2) molecular basis that underlie drug resistance in targeted cancer therapy against hyperactive RAS/RAF/MEK/ERK signaling, and (3) develop novel RAF/MEK inhibitors with broader coverage, better efficacy and less side effects.
Education
Doctor of Philosophy
University of Colorado, United States
Master of Science
Peking University, China
Bachelor of Science
East China University of Science & Technology, China